Series B COMMON STOCK PURCHASE WARRANT ZYVERSA THERAPEUTICS, INC.ZyVersa Therapeutics, Inc. • August 1st, 2024 • Pharmaceutical preparations
THIS Series B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time or times on or after [________], 2024 (the “Initial Exercise Date”) (except that [•] shares of common stock shall be exercisable for a period of eighteen (18) months commencing on or after the Stockholder Approval Date) (the “Stockholder Approval Warrants”) and on or prior to 5:00 p.m. (New York City time) on the eighteen-month anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from ZyVersa Therapeutics, Inc., a Delaware corporation (the “Company”), up to [●] shares of common stock, par value $0.0001 per share (the “Common Stock”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall
CONFIDENTIAL August 1, 2024ZyVersa Therapeutics, Inc. • August 1st, 2024 • Pharmaceutical preparations • New York
The purpose of this financial advisory agreement (this “Agreement”) is to confirm the engagement of A.G.P./Alliance Global Partners (“A.G.P.”) by ZyVersa Therapeutics, Inc. (the “Company”) to render Financial Services (as defined below) to the Company.
